Biotech · Private company · New Haven, CT, US
Allyx Therapeutics
Track this companyFree. Adds Allyx Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials41 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline7
- BMS-984923Phase 1 · Alzheimer DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- BMS-984923Phase 1 · Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- BMS-984923Phase 1 · Drug Drug Interaction (DDI)ClinicalTrials.gov · fetched Nov 12, 2026
- BMS-9894923Phase 1 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CaffeinePhase 1 · Drug Drug Interaction (DDI)ClinicalTrials.gov · fetched Nov 12, 2026
- dextromethorphanPhase 1 · Drug Drug Interaction (DDI)ClinicalTrials.gov · fetched Nov 12, 2026
- MidazolamPhase 1 · Drug Drug Interaction (DDI)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe SubstratesPHASE1 · ACTIVE_NOT_RECRUITING · started Nov 4, 2024ClinicalTrials.gov NCT06632990 · fetched Nov 12, 2026
- A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson'sPHASE1 · UNKNOWN · started Mar 15, 2024ClinicalTrials.gov NCT06309147 · fetched Nov 12, 2026
- A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's DiseasePHASE1 · COMPLETED · started Mar 28, 2023ClinicalTrials.gov NCT05804383 · fetched Nov 12, 2026
- Food Effect Study of BMS-984923 in Healthy Older Adult VolunteersPHASE1 · UNKNOWN · started Jan 10, 2023ClinicalTrials.gov NCT05817643 · fetched Nov 12, 2026
NIH awards2
- Clinical evaluation of BMS-984923 metabolism.Fiscal year 2025 · $1.7MNIH RePORTER 5SB1AG087748-02 · fetched Nov 12, 2026
- Clinical evaluation of BMS-984923 metabolism.Fiscal year 2024 · $1.7MNIH RePORTER 1SB1AG087748-01 · fetched Nov 12, 2026